Kashley Jones
Payments from drug & device makers
Across 93 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$768
- AstraZeneca$165
- Lilly USA, LLC$106
- Amgen$86
- Novo Nordisk$72
- Xeris Pharmaceuticals, Inc.$65
- plus $441 from 19 others
What the payments were for
- Food & beverage$1,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $768 |
| AstraZeneca | 10 | $165 |
| Lilly USA, LLC | 6 | $106 |
| Amgen | 5 | $86 |
| Novo Nordisk | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $65 |
| Pfizer | 3 | $47 |
| Organon | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Johnson & Johnson | 2 | $31 |
| Lundbeck LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Globus Medical | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$1,703 in reported general payments places this provider in the 80th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $24,003 |
| JardianceEmpagliflozin | 11 | $20,412 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $12,206 |
| XareltoRivaroxaban | 17 | $11,692 |
| Omeprazole | 86 | $1,453 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $1,429 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,054 |
| Ondansetron Hcl | 22 | $732 |
| Gabapentin | 30 | $729 |
| Levothyroxine Sodium | 94 | $724 |
| Bupropion XlBupropion Hcl | 30 | $666 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $597 |
| Atorvastatin Calcium | 64 | $584 |
| Tramadol Hcl | 27 | $580 |
| Cefdinir | 21 | $573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $72 | $24,00317 claims |
| Johnson & JohnsonXarelto | $31 | $11,69217 claims |
| PfizerPaxlovid | $47 | $1,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,460 family providers in Utah.
Other family in Salem
- Christopher GesselSalem$29K
- Colton JacksonSalem$8K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.